Ken Griffin Aldeyra Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.19 - $6.32 $117,711 - $233,208	36,900 Added 113.54%	69,400 $374,000
Q2 2024 Aug 14, 2024	BUY	$3.25 - $4.72 $12,350 - $17,936	3,800 Added 13.24%	32,500 $107,000
Q1 2024 May 15, 2024	SELL	$2.77 - $4.22 $103,875 - $158,250	-37,500 Reduced 56.65%	28,700 $93,000
Q4 2023 Feb 14, 2024	SELL	$1.47 - $6.06 $73,353 - $302,394	-49,900 Reduced 42.98%	66,200 $232,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $154,583 - $206,448	-25,300 Reduced 17.89%	116,100 $775,000
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $351,945 - $588,555	-49,500 Reduced 25.93%	141,400 $1.19 Million
Q1 2023 May 15, 2023	BUY	$5.77 - $9.93 $454,098 - $781,491	78,700 Added 70.14%	190,900 $1.9 Million
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $510,540 - $712,545	100,500 Added 858.97%	112,200 $780,000
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $47,120 - $95,976	-12,400 Reduced 51.45%	11,700 $62,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $295M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.